"Use of the Pfizer Pentavalent Meningococcal Vaccine among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023" published in MMWR
CDC published Use of the Pfizer Pentavalent Meningococcal Vaccine among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023 in the April 18 issue of MMWR.
ACIP recommends use of this product (MenABCWY, Penbraya, Pfizer) as an option when vaccination against all five vaccine-preventable meningococcal serogroups (A, B, C, W, and Y) is needed at the same visit and the Trumenba (Pfizer) brand of MenB vaccine is used for the MenB series. ACIP recommends this product may be administered to any person age 10 years or older, including off-label use in adults older than age 25 years. Doses of Penbraya should not be administered less than 6 months apart. A portion of the summary appears below.
The pentavalent meningococcal vaccine (MenACWY-TT/MenB-FHbp [Penbraya, Pfizer Inc.]) protects against N. meningitidis serogroups A, B, C, W, and Y and is licensed for use among persons aged 10–25 years. . . .
On October 25, 2023, the Advisory Committee on Immunization Practices recommended that MenACWY-TT/MenB-FHbp may be administered to persons aged ≥10 years when both a quadrivalent meningococcal conjugate vaccine (MenACWY) and meningococcal B vaccine (MenB) are indicated at the same visit. . . .
MenACWY-TT/MenB-FHbp is the first pentavalent meningococcal vaccine approved for protection against serogroups A, B, C, W, and Y. Different manufacturers’ MenB vaccines are not interchangeable; when MenACWY-TT/MenB-FHbp is administered, subsequent doses of MenB should be from the same manufacturer (Pfizer Inc.). . . .
Access the MMWR article in HTML or PDF.
Related Links
Back to top
CDC reminds clinicians: nirsevimab (Beyfortus) season has ended in most jurisdictions; prepare to resume in October 2024 The 2023 ACIP recommendation for administration of nirsevimab (Beyfortus, Sanofi), the long-acting monoclonal antibody product for prevention of RSV disease in infants and toddlers, takes into account the seasonal nature of RSV infection. Nirsevimab use should begin October 1 and end March 31 in jurisdictions with RSV seasonality typical of the contiguous United States (the “lower 48”). Based on this, in most facilities, nirsevimab inventory should be stored properly for the coming months until its use resumes in October 2024.
Alaska and tropical climates may have RSV circulation patterns that differ from most of the contiguous United States. Locations with tropical climates include southern Florida, Hawaii, Guam, Puerto Rico, U.S. Virgin Islands, and U.S.-affiliated Pacific Islands. Providers in these jurisdictions should follow state, local, or territorial guidance on timing of nirsevimab administration.
Related Links
Immunize.org updates its resource for healthcare professionals: “Don’t Be Guilty of These Preventable Errors in Vaccine Administration!”
Immunize.org recently updated its resource for healthcare professionals: Don't Be Guilty of These Preventable Errors in Vaccine Administration! We updated resources and broken web links and removed references to the Menactra (Sanofi) brand of MenACWY, which is no longer available.
Related Links
Back to top
Use Immunize.org's revised temperature logs: now with more room to write min/max temperatures In March, Immunize.org updated its entire suite of materials to align with CDC’s Vaccine Storage and Handling Toolkit. The materials now accommodate two options for monitoring temperatures in standard freezers or refrigerators:
- CDC-preferred continuous digital data loggers that display minimum and maximum temperatures (min/max) or
- Other acceptable temperature monitoring devices without min/max displays
In April, Immunize.org incorporated reader feedback to create more room on each of the four temperature logs to document minimum and maximum temperatures on the chart:
 
 
Related Links
Back to top
Immunize.org updates "Strategies to Improve Adult Vaccination Coverage" Immunize.org recently revised its 2-page resource titled Strategies to Improve Adult Vaccination Coverage. We removed references to the Menactra (Sanofi) brand of MenACWY, which is no longer available.
Related Links
In time for NIIW: Vaccinate Your Family launches #ProtegeATuBaby, a bilingual initiative encouraging infant immunization National Infant Immunization Week (NIIW), April 22–29, highlights the importance of protecting infants from vaccine-preventable diseases. Since 1994, hundreds of communities have celebrated the crucial role vaccination plays in protecting our children, communities, and public health.
To observe NIIW, Vaccinate Your Family (VYF) now offers the Spanish-English #ProtegeATuBaby Sharing Toolkit for downloadable social media graphics, key messages about vaccines recommended for babies, and sharable animated videos. Remember to use hashtag #ProtegeATuBaby when sharing on social media and tag @vaccinateyourfamily (@vaxyourfam on X) so VYF can amplify your posts.
CDC makes it simple to plan your NIIW activities by using their promotional materials including English and Spanish logos, sample social media content, social graphics, and key messages. Please share your posts using the hashtag #ivax2protect.
Related Links
Back to top
“My patient just turned 65 and has never had a pneumococcal vaccine. What are my options now?” Watch the 1-minute answer, part of the Ask the Experts Video Series on YouTube. This week, our featured episode from the Ask the Experts Video Series is My patient just turned 65 and has never had a pneumococcal vaccine. What are my options now? The video briefly describes routine pneumococcal vaccination of adults turning 65.
The 1-minute video is available on our YouTube channel, along with our full collection of quick video answers to popular Ask the Experts questions.
Like, follow, and share Immunize.org’s social media accounts and encourage colleagues and others interested in vaccination to do likewise:
Immunize.org's Influenza Vaccination Honor Roll for healthcare worker vaccination requirements welcomes one new facility Immunize.org's Influenza Vaccination Honor Roll recognizes facilities that take a stand for patient safety by implementing policies requiring healthcare personnel influenza vaccination. Immunize.org recently welcomed an additional healthcare organization.
- Silver Lake Hospital, Newark, NJ
Eligibility:
- Eligible organizations: hospitals, long-term care facilities, medical practices, pharmacies, professional organizations, health departments, and other government entities
- Requirements:
- Your policy must require influenza vaccination for all staff
- The application must describe measures to prevent transmission of influenza from unvaccinated personnel to patients (e.g., masking for the entire work shift)
Related Links
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
Immunize.org Website and Clinical Resources
Spotlight on the website: Resources to enhance vaccine confidence and address concerns
This week, we spotlight Immunize.org’s clinical resources for improving confidence in and addressing concerns about vaccinations. These provide medical professionals with practical resources that can be shared with patients and parents.
Located under the Clinical Resources menu, the Vaccine Confidence & Addressing Concerns section contains both an overview page and a list of topics.
The Overview Page lists topics such as safety, scheduling, religious concerns, and more than 100 personal accounts of people and families who have been affected by vaccine-preventable diseases. This page also provides links to educational materials from other trusted organizations.
One of these topics is “Improving the Vaccination Experience.” Anxiety about needles and injections is common among children and adults, so we developed resources to help providers reduce vaccine-related pain and anxiety. These are available as printable documents for both vaccine providers and recipients as well as video and webinar formats.
Back to top
Hip-hop themed videos highlight reasons to be vaccinated
As part of the CDC-funded National Network to Innovate for COVID-19 and Adult Vaccine Equity led by the Michigan State University School of Public Health, the Media Genesis team designed a public service announcement campaign highlighting pioneering black scientists and encouraging residents of black communities to “listen to the science” and get the COVID-19 vaccine. The campaign was created in the form of hip-hop music videos. Local musicians from Detroit, Charlotte, and Baltimore contributed lyrics and recorded the vocals and the music was created by Third V Modern Entertainment.
Media Genesis Solutions also created Black Pioneers in Science videos to increase awareness of scientific achievement in the African American community. One of these videos is on Dr. Kizzmekia Corbett, whose COVID-19-related work was central to the development of the Moderna mRNA vaccine and the Eli Lilly therapeutic monoclonal antibody.
View and share the Listen to the Science and Black Pioneers in Science videos.
Back to top
Before we run out! Place your order for these sturdy, laminated versions of the 2024 U.S. immunization schedules from Immunize.org.
Laminated versions of the 2024 U.S. child and adolescent immunization schedule and the 2024 U.S. adult immunization schedule are shipping. We anticipate selling out, so put in your order now!
While the schedules are available online from CDC at no cost, Immunize.org’s printed, laminated booklets are ideal for use in any busy healthcare setting where vaccinations are given.
- Durable: their tough coating can be wiped down, and they’re durable enough to stand up to a year's worth of use
- Format: each schedule is produced in a 16-page, 8.5” X 11” booklet format; with color coding for easy reading, our laminated schedules replicate the original CDC formatting, including all tables and notes
- Easy access to CDC updates: CDC added an online addendum page to the schedule, where new recommendations from ACIP made during 2024 can be posted. The laminated schedule addendum pages include custom QR codes you can scan to view or print the current CDC addendum from CDC's website, as needed.
- Adult schedule bonus content: the adult schedule includes a bonus page with Immunize.org’s popular 1-page handout summarizing the dose, route, and needle size recommendations for all vaccines and recipients
 
Pricing
1 copy: $10.00
2–4 copies: $9.50 each
5–19 copies: $8.50 each
20–99 copies: $7.50 each
100–499 copies: $6.00 each
500–999 copies: $5.00 each
1,000–1,999 copies: $4.00 each
2,000+ copies: $3.25 each
Visit the Shop Immunize.org: Laminated Schedules web page to view images of all the pages, to download the order form, and to order today!
For additional information, call 651-647-9009 or email [email protected].
Related Links
Back to top
"Incidence of Adolescent Syncope and Related Injuries following Vaccination and Routine Venipuncture" published in Journal of Adolescent Health
In the December 9 issue, Journal of Adolescent Health published Incidence of Adolescent Syncope and Related Injuries following Vaccination and Routine Venipuncture. We have summarized a portion of the results section.
Chart validation in this study confirmed:
- Vaccine-associated syncope at a rate of 3.0 per 10,000 vaccination events
- Venipuncture-associated syncope at a rate of 16.3 per 10,000 venipuncture events
Incidence of vaccine-associated syncope increased with each additional simultaneously administered vaccine, from 1.5 per 10,000 vaccination events after a single vaccine to 9.9 per 10,000 vaccination events after three or more vaccines.
The study reports that syncope resulted in injury in about 15% of both vaccine and venipuncture events.
Immunize.org offers resources to vaccine recipients and healthcare providers that describe vaccination-associated fainting and simple measures to reduce the risk of fainting. Download Immunize.org's handouts, Vaccination-Related Syncope: Information for Healthcare Personnel and Fainting Related to Vaccination: What You Need to Know (also available in Spanish), to use in your practice.
Related Links
"Durability of Original Monovalent mRNA Vaccine Effectiveness against COVID-19 Omicron–Associated Hospitalization in Children and Adolescents—United States, 2021–2023" published in MMWR
CDC published Durability of Original Monovalent mRNA Vaccine Effectiveness against COVID-19 Omicron–Associated Hospitalization in Children and Adolescents—United States, 2021–2023 on April 18 in MMWR. A portion of the summary appears below.
During December 19, 2021–October 29, 2023, receipt of ≥2 doses of an original monovalent mRNA COVID-19 vaccine was 52% effective against pediatric COVID-19 hospitalization and 57% effective against critical illness related to COVID-19, when the last dose was received within the 4 months preceding hospitalization, but protection decreased over time. . . .
These findings support existing recommendations that children and adolescents aged 5–18 years remain up to date with COVID-19 vaccination given low vaccination coverage and waning effectiveness over time against COVID-19–related hospitalizations.
Access the MMWR article in HTML or PDF.
Related Link
- CDC: MMWR main page providing access to the MMWR family of publications
"COVID-19 Vaccination Coverage, and Rates of SARS-CoV-2 Infection and COVID-19–Associated Hospitalization among Residents in Nursing Homes—National Healthcare Safety Network, United States, October 2023–February 2024" published in MMWRCDC published COVID-19 Vaccination Coverage, and Rates of SARS-CoV-2 Infection and COVID-19–Associated Hospitalization among Residents in Nursing Homes—National Healthcare Safety Network, United States, October 2023–February 2024 on April 18 in MMWR. A portion of the summary appears below.
Nursing home residents are at increased risk for severe COVID-19. . . .
Each week during October 16, 2023–February 11, 2024, 14.9%–26.1% of nursing homes reported one or more SARS-CoV-2 infections. Weekly rates of COVID-19–associated hospitalization ranged from 3.8 to 7.1 per 10,000 nursing home residents. By February 11, 2024, only 40.5% of residents had received an updated 2023–2024 COVID-19 vaccine. . . .
During the 2023–24 respiratory virus season, nursing home residents continued to have high rates of COVID-19–associated hospitalization, and up-to-date COVID-19 vaccination coverage remained low. Ongoing surveillance for SARS-CoV-2 infections and COVID-19–associated hospitalizations in this population is necessary to develop and evaluate evidence-based interventions for protecting nursing home residents.
Access the MMWR article in HTML or PDF.
Related Links
"COVID-19 Vaccination Site Accessibility, United States, December 11, 2020–March 29, 2022" published in Emerging Infectious DiseasesIn the May 2024 issue, Emerging Infectious Diseases published COVID-19 Vaccination Site Accessibility, United States, December 11, 2020–March 29, 2022. The abstract appears below.
During December 11, 2020–March 29, 2022, the US government delivered 700 million doses of COVID-19 vaccine to vaccination sites, resulting in vaccination of 75% of US adults during that period. We evaluated accessibility of vaccination sites. Sites were accessible by walking within 15 minutes by 46.6% of persons, 30 minutes by 74.8%, 45 minutes by 82.8%, and 60 minutes by 86.7%. When limited to populations in counties with high social vulnerability, accessibility by walking was 55.3%, 81.1%, 86.7%, and 89.4%, respectively. By driving, lowest accessibility was 96.5% at 15 minutes. For urban/rural categories, the 15-minute walking accessibility between noncore and large central metropolitan areas ranged from 27.2% to 65.1%; driving accessibility was 79.9% to 99.5%. By 30 minutes driving accessibility for all urban/rural categories was >95.9%. Walking time variations across jurisdictions and between urban/rural areas indicate that potential gains could have been made by improving walkability or making transportation more readily available.
Virtual: NFID hosts webinar titled “Combating the Resurgence of Measles and Other Preventable Diseases” on April 30 at 11:00 a.m. (ET); CME credit offered
NFID will host a webinar titled Combating the Resurgence of Measles and Other Preventable Diseases, 11:00 a.m.–12:00 p.m. (ET) on April 30. NFID Medical Director Robert H. Hopkins, Jr., MD, will moderate the discussion featuring Yvonne A. Maldonado, MD, Stanford University; Sean T. O’Leary, MD, MPH, University of Colorado School of Medicine and Children’s Hospital Colorado; and Tami H. Skoff, MS, epidemiologist, CDC. This webinar will feature a panel discussion addressing vaccine recommendations and effective strategies to reduce the U.S. burden of measles, pertussis, and polio.
CME credit is available. There is no fee to participate in this activity, but preregistration is required.
Register for the webinar.
NFID hosts monthly webinars to increase awareness of the importance of infectious disease prevention and treatment. CME, CNE, and CPE credits are available for select recordings. View all archived NFID webinars.
Back to top
|
